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Deletions and mutations affecting lymphoid transcription factorIKZF1 (IKAROS) are associated with an increased relapse riskand poor outcome in B-cell precursor acute lymphoblastic
leukemia. However, additional genetic events may either enhance or
negate the effects of IKZF1 deletions on prognosis. In a large discovery
cohort of 533 childhood B-cell precursor acute lymphoblastic leukemia
patients, we observed that single-copy losses of BTG1were significantly
enriched in IKZF1-deleted B-cell precursor acute lymphoblastic leukemia
(P=0.007). While BTG1 deletions alone had no impact on prognosis, the
combined presence of BTG1 and IKZF1 deletions was associated with a
significantly lower 5-year event-free survival (P=0.0003) and a higher 
5-year cumulative incidence of relapse (P=0.005), when compared with
IKZF1-deleted cases without BTG1 aberrations. In contrast, other copy
number losses commonly observed in B-cell precursor acute lymphoblas-
tic leukemia, such as CDKN2A/B, PAX5, EBF1 or RB1, did not affect the
outcome of IKZF1-deleted acute lymphoblastic leukemia patients. To
establish whether the combined loss of IKZF1 and BTG1 function coop-
erate in leukemogenesis, Btg1-deficient mice were crossed onto an Ikzf1
heterozygous background. We observed that loss of Btg1 increased the
tumor incidence of Ikzf1+/- mice in a dose-dependent manner. Moreover,
murine B cells deficient for Btg1 and Ikzf1+/- displayed increased resistance
to glucocorticoids, but not to other chemotherapeutic drugs. Together,
our results identify BTG1 as a tumor suppressor in leukemia that, when
deleted, strongly enhances the risk of relapse in IKZF1-deleted B-cell pre-
cursor acute lymphoblastic leukemia, and augments the glucocorticoid
resistance phenotype mediated by the loss of IKZF1 function. 
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ABSTRACT
Introduction 
Acute lymphoblastic leukemia (ALL) is the most com-
mon form of cancer in children and is characterized by
recurrent genetic aberrations and chromosomal abnormal-
ities, which represent distinct genetic subtypes that are
used for risk stratification.1 In the past, we and others have
demonstrated that genomic alterations affecting the lym-
phoid transcription factor gene IKZF1 represent a strong
prognostic factor associated with relapse in childhood 
B-cell precursor acute lymphoblastic leukemia (BCP-
ALL).2-5 Recently, we established that loss of IKZF1 affects
glucocorticoid (GC)-mediated gene regulation and confers
GC resistance in BCP-ALL.6 Deletion of IKZF1 is a hall-
mark of BCR-ABL1-positive BCP-ALL,7 and within this
high-risk cytogenetic subtype, IKZF1 loss is associated
with an even worse outcome.8 IKZF1 gene lesions are also
frequently present in high-risk leukemias with a
Philadelphia- or BCR-ABL1-like expression signature,2,5,9
which often carry activated tyrosine kinases (i.e., ABL1,
PDGFRB, JAK2, FLT3) or mutations targeting the RAS
pathway.10-12 Mouse studies have confirmed that two of
these genomic alterations, namely BCR-ABL1 and mutant
RAS, cooperate with loss of IKZF1 during leukemic trans-
formation.13,14 On the other hand, ERG gene deletions con-
stitute a specific subtype of BCP-ALL with favorable out-
come, despite the frequent co-occurrence of IKZF1 dele-
tions.15,16 Thus, specific genetic interactions may modulate
the tumor suppressive functions of IKZF1 during leukemia
development at initial diagnosis and at relapse after
chemotherapy treatment. 
Besides IKZF1, many other recurrent genetic aberrations
have been observed in BCP-ALL, which include deletions
affecting BTG1, CDKN2A/B, EBF1, ETV6, PAX5, RAG1,
RB1 and TCF3.17-19 For some of these co-occurring genetic
lesions, synergistic effects have been reported on leukemia
development. For example, loss of Rag1 was shown to
accelerate the onset of B-cell lymphoblastic leukemia in
Cdkn2a/p19Arf-deficient mice,20 while increasing the inci-
dence of T-cell lymphomas in Tcf3–/– mice.21 Furthermore,
combined heterozygosity for Ebf1 and Pax5 results in a
strong increase in the frequency of pro-B-cell leukemia in
mice.22
Herein we describe the impact of deletions affecting the
transcriptional coregulator B-cell translocation gene 1
(BTG1), in co-occurrence with IKZF1 loss on both leuke-
mogenesis as well as outcome. We demonstrate that
BTG1 deletions are enriched in IKZF1-deleted pediatric
BCP-ALL cases, and correlate with increased relapse risk
in this patient group. Using mouse knockout models, we
further demonstrate that loss of Btg1 cooperates with
Ikzf1+/- in the onset of ALL. Finally, our data indicate that
both BTG1 and IKZF1 are important determinants of the
GC therapy response, and that combined loss of these
tumor suppressors enhances GC resistance. 
Methods 
Clinical samples
The discovery cohort comprised of 533 pediatric patients with
newly diagnosed BCP-ALL from three consecutive Dutch
Childhood Oncology Group trials (DCOG ALL-8, ALL-9 and ALL-
10) and two German Cooperative ALL trials (COALL 06-97 and
07-03). The validation cohort consisted of 515 pediatric patients
enrolled in the Australian and New Zealand Children’s
Haematology and Oncology Group (ANZCHOG) ALL8 protocol.
In accordance with the Declaration of Helsinki, written informed
consent was obtained from parents or legal guardians, and institu-
tional review boards approved the use of excess diagnostic mate-
rial for research purposes. Details on the patient cohorts, treat-
ment regimens and outcomes, were described previously.5,23,24 
Statistics patient data 
Cumulative incidence of relapse (CIR) was estimated using a
competing risks model, equality of CIRs was tested with Gray's
test. Relapse and non-response to induction chemotherapy were
considered as events, with death and secondary malignancy as
competing events. Event-free survival (EFS) was calculated with
non-response, relapse, secondary malignancy and death consid-
ered as events. EFS probabilities were estimated using the Kaplan-
Meier method, and survival data between groups were compared
using univariate and multivariate Cox regression analyses. The
proportions of patients with IKZF1 and other B-cell development
gene deletions as well as other categorical variables were com-
pared using the Fisher’s exact test. All P-values are two-sided, and
a significance level of 0.05 or less was considered to be significant.
Analyses were performed in R 3.0.1 (2013-05-16), using the pack-
ages cmprsk version 2.2-7, mstate version 0.2.7, and survival ver-
sion 2.37-4.25-27
Mice
Btg1 and Ikzf1 (IkNeo) knockout lines have been described previ-
ously,28,29 and were intercrossed on a C57Bl/6J background. Mice
were maintained under specific pathogen-free conditions at our
Central Animal Laboratory facility. Genotyping of the offspring
was performed by polymerase chain reaction (PCR) (primer
sequences are listed in the Online Supplementary Table S1). Animal
experiments were approved by the Animal Experimental
Committee of the Radboud university medical center and were
performed in accordance with institutional and national guidelines. 
Functional characterization of murine lymphocytes
Detailed information on functional characterization of normal
and leukemic lymphocytes by flow cytometry, immunohisto-
chemistry, immunoglobulin (IG)/T-cell receptor (TR) PCR and cell
viability assays can be found in the Online Supplementary Methods
section. To analyze the glucocorticoid response in B lymphocytes,
mononuclear splenocytes were isolated from wild-type and the
different knockout mice, and stimulated in vitro with 5 mg/mL
lipopolysaccharide (LPS) for 48 hours. The obtained activated 
B lymphocytes (≥ 80% B220+) were isolated by ficoll gradient and
cultured for another 48 hours in the absence or presence of the
synthetic glucocorticoids prednisolone or dexamethasone.
Thereafter, relative cell viability was assessed by MTS assay and
AnnexinV/7-AAD staining.  
Results 
BTG1 deletions are enriched in IKZF1-deleted pediatric
BCP-ALL
Gene deletion of the tumor suppressor IKZF1, creating
either dominant-negative IKZF1 isoforms or haploinsuffi-
ciency, is an important predictor of poor outcome in BCP-
ALL,2-5 but to what extent other additional common single
gene deletions, such as CDKN2A/B, PAX5, BTG1, ETV6,
EBF1 or RB1 impact the prognostic value of IKZF1 has not
been clearly established. To address this question, we
studied a previously described childhood BCP-ALL cohort
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of 533 cases enrolled in consecutive DCOG and COALL
trials.5 The representation of the different BCP-ALL sub-
types was similar between the DCOG and COALL
cohorts, and comparable to that described in the literature
(Online Supplementary Table S2). We identified 105 BCP-
ALL patient samples containing an IKZF1 deletion. Within
the IKZF1-deleted group, we observed a significant
enrichment for BTG1 deletions (P=0.007), where 17 of the
105 IKZF1-deleted cases (16%) harbored BTG1 deletions
as compared to 31 of the 428 IKZF1 wild-type cases (7%)
(Table 1). These focal BTG1 deletions mainly covered the
second exon of BTG1 and downstream adjacent
sequences, as described previously.30 Similarly, deletions
affecting PAX5 (P<0.0001), CDKN2A/B (P=0.0003) and
RB1 (P=0.026) were present at higher frequencies in 
IKZF1-deleted cases, whilst this was not observed for
EBF1 or ETV6 deletions (Table 1). To the contrary, in the
BTG1-deleted group we observed significant enrichment
for IKZF1 (P=0.007), EBF1 (P=0.0011), RB1 (P=0.042), and
ETV6 (P=0.0046) deletions (Online Supplementary Table S3),
which is in agreement with our previous findings.30
Previously, it has been shown that both IKZF1 and BTG1
deletions are strongly enriched in the cytogenetic 
BCR-ABL1 subtype.7,31 Consistent with this notion, we
observed that of 24 BCR-ABL1-positive cases, 7 (29%) har-
bored deletions in both IKZF1 and BTG1 (Table 2), which
represents 47% of IKZF1-deleted and 100% of the 
BTG1-deleted cases found in the BCR-ABL1-positive
group (Table 2).
Combined deletions of BTG1 and IKZF1 predict inferior
outcome in BCP-ALL
We next compared clinical characteristics of
BTG1;IKZF1 double-deleted cases, sole deletion of IKZF1
and sole deletion of BTG1 cases, and cases without IKZF1
or BTG1 deletion in our complete childhood BCP-ALL
cohort. The characteristics of these four groups were sim-
ilar to the total cohort with respect to gender and treat-
ment protocol (Table 2). The double-deleted and sole dele-
tion of IKZF1 groups contained more patients over 10
years of age and increased white blood cell counts, and
hence more National Cancer Institute (NCI)-Rome criteria
high-risk cases32 (Table 2). We compared the EFS and CIR
between cases with both IKZF1 and BTG1 deletions
(BTG1-del;IKZF1-del, n=17) with the cases of sole dele-
tion of IKZF1 (BTG1-wt;IKZF1-del, n=88) (Figure 1A,B).
The 5-year CIR in IKZF1- plus BTG1-deleted cases was
53% ± 13% compared with 28% ± 5% in the cases of sole
deletion of IKZF1 (P=0.005; Table 3A). Similarly, the 5-
year EFS was lower in double-deleted cases compared
with the cases of sole deletion of IKZF1 (HR 3.5,
P=0.0003; Table 3A). In contrast, the cases of sole deletion
of BTG1 (BTG1-del;IKZF1-wt, n=31) showed a similar
outcome (5-year CIR:10% ± 6%) to the reference cases
without IKZF1 or BTG1 deletions (n=397; 5-year
CIR:13% ± 2%). The synergistic effect of loss of BTG1
and IKZF1 on outcome remained after correction for sub-
type in the Cox model (Table 3A), and after leaving out the
BCR-ABL1-positive cases (Figure 1C,D; Table 3B). For the
BCR-ABL1-positive cases, BTG1 deletions did not further
impact the poor treatment outcome as observed for the
cases of sole deletion of  IKZF1 (Figure 1E,F; Table 3C). 
As deletions of PAX5, CDKN2A/B and RB1were similar-
ly enriched in IKZF1-deleted BCP-ALL, we examined the
impact of these deletions on the outcome of IKZF1-delet-
ed cases. In contrast to BTG1;IKZF1 double-deleted
patients, the outcome of patients with co-occurring PAX5,
CDKN2A/B or RB1 deletions did not differ from cases of
sole deletion of  IKZF1 (Figure 2; Online Supplementary
Table S4). Similarly, co-occurrences of IKZF1 deletions
with either EBF1 or ETV6 deletions did not affect outcome
compared with the sole deletion of IKZF1. To validate our
findings, we analyzed the Australian and New Zealand
ANZCHOG ALL8 cohort (n=515)23,24 to assess the prog-
nostic value of BTG1;IKZF1 double-deletions. In this
cohort, 6 out of 11 BTG1-del;IKZF1-del patients devel-
oped a relapse (Online Supplementary Figure S1). The 5-year
CIR in the BTG1;IKZF1 double-deleted group was 61% ±
19% versus 35% ± 6% in the group with the sole deletion
of IKZF1 (P=0.19; Table 3D). Hence, the same trend was
observed in this independent validation cohort, albeit sta-
tistically non-significant. Together, these data indicate that
BTG1 deletions in an unselected leukemia population
have no prognostic value, but BTG1 copy number losses
specifically exacerbate the effects of IKZF1 deletion on
inferior outcome in BCP-ALL.
Combined BTG1 and IKZF1 deletions affect outcome
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Table 1. Co-occurrence of IKZF1 deletion with other common gene deletions in BCP-ALL.
IKZF1 no deletion IKZF1 deletion Fisher’s Test
n % n % P Odds ratio
BTG1 no deletion 397 0.93 88 0.84 0.0071 2.5
BTG1 deletion 31 0.07 17 0.16
PAX5 no deletion 330 0.77 55 0.52 1.40E-06 3.1
PAX5 deletion 98 0.23 50 0.48
CDKN2A/B no deletion 298 0.70 53 0.50 3.40E-04 2.2
CDKN2A/B deletion 130 0.30 52 0.50
EBF1 no deletion 405 0.95 96 0.91 0.25 1.6
EBF1 deletion 23 0.05 9 0.09
RB1 no deletion 400 0.93 91 0.87 0.026 2.2
RB1 deletion 28 0.07 14 0.13
ETV6 no deletion 296 0.69 80 0.76 0.19 0.7
ETV6 deletion 132 0.31 25 0.24
Leukemia predisposition in Btg1 knockout mice
Although deletions affecting the BTG1 gene are a fre-
quent event in BCP-ALL, a direct role for BTG1 in
leukemia development has not been reported. Therefore,
we first examined the tumor suppressive function of
BTG1 using a constitutive Btg1 knockout line harboring a
Neo-cassette in the first coding exon.28 We previously
reported that these Btg1 knockout mice display defective
B-cell development with a 25% reduction in the amount
of progenitor B cells within the bone marrow compart-
ment, mainly affecting the pre-B and immature B-cell
stage.33 Furthermore, Btg1 is required for optimal prolifer-
ative expansion of early progenitor B cells in methylcellu-
lose in response to interleukin-7. At the same time, there
was no obvious defect in the development of myeloid and
T-lymphoid cells in these Btg1-deficient animals.33 In the
study herein, mice that carried either one or two copies of
the Btg1 knockout allele were followed over a period of 18
months, along with control littermates. About 6%
(n=3/49) of the wild-type C57BL6/J mice developed B-cell
lymphomas between the age of 14 and 18 months (Table
4), which is consistent with previous observations.34
Within the same time period 6% of the Btg1+/- (n=2/34)
and 18% of the Btg1-/- (n=6/33) mice developed T-cell
leukemia exclusively (Table 4), characterized by enlarged
primary lymphoid organs, such as the spleen and lymph
nodes, and focal infiltration of leukemic T cells into
peripheral organs, such as the lungs and liver. These 
Btg1-deficient T-cell leukemias expressed the T-cell surface
marker CD3, and displayed clonal T-cell receptor (TR)
rearrangements (Figure 3B). In addition, these CD3+ T-cell
leukemias not only showed increased expression of the T-
cell activation marker CD44, but also large numbers of
B220+ cells within the infiltrated areas of tissues, such as
the liver or lungs, and affected lymph nodes (Online
Supplementary Figure S2). There was no evidence for clonal
immunoglobulin gene rearrangements in these Btg1-/-
T-cell leukemias (Online Supplementary Figure S2), suggest-
ing the presence of a substantial number of non-malignant
B lymphocytes in proximity to these leukemic T cells.
These data show that, although somatic BTG1 deletions
predominantly occur in BCP-ALL, Btg1-deficiency in the
mouse germline predisposes exclusively to T-cell malig-
nancies. This predilection for T-lineage leukemias is also
observed in other knockout mouse models targeting genes
commonly deleted in BCP-ALL, such as Ikzf1 mutant
mice.35,36
Loss of Btg1 increases leukemia incidence in Ikzf1+/- mice
To investigate cooperation between BTG1 and IKZF1
during leukemogenesis, we intercrossed Btg1-deficient
mice with haplodeficient Ikzf1 mice using the IkNeo mouse
line,29 which harbors a Neo-floxed knock-in allele com-
bined with a Pax5-IRES-GFP complementary DNA
(cDNA) at the first coding exon of Ikzf1, thereby creating
an Ikzf1 null allele.29 These mice are only viable as a het-
erozygous knockout line (Ikzf1+/-). First, we analyzed the
phenotype of young animals (age 6-12 weeks) to assess
the effect of the Ikzf1+/- allele on Btg1-deficiency in B- and
T-lymphoid development. Ikzf1+/-mice, like Btg1-/- mice,
displayed a moderate reduction in the fraction of B220+
cells in bone marrow (BM) and the spleen (Online
B. Scheijen et al.
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Table 2. Pediatric BCP-ALL patient characteristics in the BTG1 and IKZF1 sole and BTG1;IKZF1 double-deleted groups.
Patients' BTG1-del; BTG1-wt BTG1-del; BTG1-wt; Total Fisher’s
characteristics IKZF1-del; IKZF1-del IKZF1-wt IKZF1-wt n=533 P
n=17 (3%) n=88 (20%) n=31 (6%) n=397 (74%)
n % n % n % n % n %
Sex 0.3
Female 5 29% 44 50% 11 35% 183 46% 243 46%
Male 11 71% 44 50% 20 65% 214 54% 290 54%
Age (years) 0.0054
< 10 11 65% 60 68% 26 84% 330 83% 427 80%
≥ 10 6 35% 28 32% 5 16% 67 17% 106 20%
WBC (cells/nl) 0.066
< 50 11 65% 55 62.5% 23 74% 299 76% 388 73%
≥ 50 6 35% 33 37.5% 8 26% 96 24% 143 27%
NCI-Rome 0.016
SR 8 47% 39 44% 19 61% 245 62% 311 58%
HR 9 53% 49 56% 12 39% 151 38% 221 42%
Protocol 0.54
DCOG 14 82% 63 72% 25 81% 311 78% 413 77%
COALL 3 18% 25 28% 6 19% 86 22% 120 23%
Subtype
ETV6-RUNX1 2 12% 2 2% 24 77% 126 32% 154 29% <0.0001
HeH 1 6% 16 18% 2 7% 107 27% 126 24% 0.0055
B-other 4 24% 23 26% 5 16% 75 19% 107 20% 0.41
BCR-ABL1-like 3 18% 38 43% 0 0% 51 13% 92 17% <0.0001
TCF3r 0 0% 0 0% 0 0% 19 5% 19 4% 0.093
BCR-ABL1 7 41% 8 9% 0 0% 9 2% 24 5% <0.0001
MLLr 0 0% 1 1% 0 0% 10 3% 11 2% 0.89
WBC count for 2 cases missing, NCI Risk for 1 case missing, both in the BTG1-wt ;IKZF1-wt group. del: deletion; WBC: white blood cell; NCI-Rome HR: high-risk defined by age at
diagnosis ≥ 10 years and/or WBC ≥ 50 cells/nl; HeH: high hyperdiploid (51-65 chromosomes); P-value: Fisher's exact test across the four deletions groups; wt: wild-type; DCOG:
Dutch Childhood Oncology Group; COALL: German Cooperative ALL; SR: standard-risk.
Supplementary Figure S3). This correlated with a partial
block at the pre-pro-B-cell stage (Hardy fraction A) and the
pre-B-cell stage (Hardy fraction D) in Ikzf1+/- mice (Online
Supplementary Figure S3). Btg1-/-;Ikzf1+/- mice showed an
even stronger reduction in B220+ cells, with additive
effects at both B220+CD43+ and B220+CD43– differentia-
tion stages in BM (Hardy fractions A to E) (Online
Supplementary Figure S3). In contrast, Btg1-/-;Ikzf1+/- mice,
similar to Btg1-/- and Ikzf1+/- single knockout animals,
showed no major defects in postnatal thymic T-cell devel-
opment (Online Supplementary Figure S4). 
Next, we followed Ikzf1+/-, Btg1-/-;Ikzf1+/- and Btg1-/-
;Ikzf1+/-mice for a period of 18 months. In our cohort, 14%
(n=5/36) of the Ikzf1+/- mice developed T-cell leukemia
between 3 and 18 months of age, with a median age of 12
months (Figure 3A; Table 4). Similar to Btg1-deficient
leukemia, the Ikzf1+/- T-cell leukemias showed infiltration
of CD3+ leukemic blasts into distant organs and clonal TR
rearrangements (Figure 3). Interestingly, we observed an
increased leukemia incidence upon combined loss of Btg1
and Ikzf1 (Figure 3A), which is consistent with our
hypothesis that BTG1 deletions cooperate with IKZF1
aberration to induce human BCP-ALL. We found that 26%
of the Btg1+/-;Ikzf1+/- mice (n=10/35) and 40% of the Btg1-/-
;Ikzf1+/- (n=12/30) animals developed T-cell leukemia,
while leukemias in Btg1-/-;Ikzf1+/- appeared with a slightly
shorter latency (9.4 months) relative to Ikzf1+/- mice (12.4
months) (P=0.011) (Table 4). Tumors in the Btg1-/-;Ikzf1+/-
compound mice were characterized by significantly high-
er leukocyte counts in peripheral blood compared to single
knockout animals (Figure 3B,C), and strong infiltration of
leukemic cells into the liver and lungs (Figure 3B,D), as
well as clonal TR rearrangements (Figure 3E). Flow cyto-
metric analysis of the different T-cell leukemias revealed
Combined BTG1 and IKZF1 deletions affect outcome
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Table 3. CIR and EFS analysis of BTG1;IKZF1 double-deleted pediatric BCP-ALL cases compared with cases of sole deleted IKZF1.
A
BCP-ALL1 (n=533) Univariate Multivariate
Deletion Total Relapse Death 5-yr CIR Gray EFS HR Cox EFS HR Cox
(SE) P (95% CI) P (95% CI) P
BTG1;IKZF1 17 10 2 53% (13%) 0.005 3.5 0.0003 2.5 0.043
(1.8-6.8) (1.0-5.9)
IKZF1 88 25 5 28% (5%)
BTG1 31 3 0 10% (6%)
none 397 52 12 13% (2%)
B
BCP-ALL1 without BCR-ABL1 (n=509) Univariate Multivariate
Deletion Total Relapse Death 5-yr CIR Gray EFS HR Cox EFS HR Cox
(SE) P (95% CI) P (95% CI) P
BTG1;IKZF1 10 6 1 50% (17%) 0.011 4.4 0.0007 6.7 0.00003
(1.9-10.3) (2.7-16)
IKZF1 80 21 2 26% (5%)
BTG1 31 3 0 10% (6%)
none 388 52 10 13% (2%)
C
BCP-ALL1 BCR-ABL1 only (n=24) Univariate Multivariate
Deletion Total Relapse Death 5-yr CIR Gray EFS HR Cox EFS HR Cox
(SE) P (95% CI) P (95% CI) P
BTG1;IKZF1 7 4 1 57% (22%) 0.7 0.8 0.7 ND ND
(0.3-2.5)
IKZF1 8 4 3 50% (21%)
BTG1 0 0 0
none 9 0 2 0% (0%)
D
BCP-ALL2 validation cohort (n=515) Univariate Multivariate
Deletion Total Relapse Death 5-yr CIR Gray EFS HR Cox EFS HR Cox
(SE) P (95% CI) P (95% CI) P
BTG1;IKZF1* 11 6 0 61% (19%) 0.19 01.83 0.16 ND ND
(0.8-4.2)
IKZF1 69 23 4 35%  (6%)
BTG1* 45 13 0 27%  (7%)
none** 390 55 4 13%  (2%)
1Discovery cohort: pediatric patients from consecutive DCOG/COALL trials. 2Validation cohort: pediatric patients from ANZCHOG ALL8 trial. * Report of 1 secondary malignancy
in these groups; ** Report of 6 independent secondary malignancies in this group. CIR: cumulative incidence of relapse; SE: standard error; EFS: event-free survival; HR: hazard
ratio; CI: confidence interval; multivariate: corrected for BCP-ALL subtype and stratified for study cohort (DCOG, COALL); none: neither BTG1 nor IKZF1 deletion: BCP-ALL: B-cell
precursor acute lymphoblastic leukemia; ND: not determined.
that most of the Btg1-/-;Ikzf1+/- leukemias were CD4+CD8+
double positive T cells with ongoing differentiation
towards CD4 or CD8 single positive stage (Figure 3F,
Online Supplementary Table S5). Moreover, isolated
leukemic T cells, derived from all the different genetic
backgrounds included in our studies (Ikzf1+/-, Btg1-/- and
Btg1-/-;Ikzf1+/-), could be serially transplanted into syngeneic
C57BL6/J mice giving rise to similar (oligo)clonal T-cell
leukemias (Online Supplementary Figure S5). Taken togeth-
er, our data demonstrate that loss of Btg1 cooperates with
haplodeficiency for Ikzf1 during mouse leukemia develop-
ment in a dose-dependent manner.
B. Scheijen et al.
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Figure 1. Cumulative incidence of relapse (CIR) and event-free survival (EFS) curves for pediatric BCP-ALL cases with or without IKZF1 and BTG1 deletions. (A) CIR
and (B) EFS curves for total BCP-ALL cohort (n=533), IKZF1 plus BTG1 deletion, (C) CIR and (D) EFS curves for BCP-ALL without BCR-ABL1-positive cases (n=509),
IKZF1 plus BTG1 deletion, (E) CIR (F) EFS curves for BCR-ABL1-positive cases (n=24), IKZF1 plus BTG1 deletion. Colors: black, IKZF1 and BTG1 wild-type; green,
IKZF1 wild-type, BTG1-deleted; red, IKZF1-deleted, BTG1 wild-type; blue, both BTG1- and IKZF1-deleted. For CIR graphs (A,C,E) the Gray P-value and for the EFS
graphs (B,D,F) the Cox P-value is indicated comparing BTG1-del;IKZF1-del with BTG1-wt;IKZF1-del. wt: wild-type; del: deletion; n: total number; BCP-ALL: B-cell pre-
cursor acute lymphoblastic leukemia.
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Figure 2. Cumulative incidence of relapse (CIR) curves for pediatric BCP-ALL cases with or
without IKZF1 deletions in combination with other single common gene deletions. (A) IKZF1
plus PAX5, (B) IKZF1 plus CDKN2A/B, (C) IKZF1 plus RB1, (D) IKZF1 plus EBF1, (E) IKZF1 plus
ETV6 (n=533). Colors: black, none of the indicated deletions; green, IKZF1 wild-type, indicated
gene deleted; red, IKZF1-deleted, indicated gene wild-type; blue, both IKZF1 and indicated
gene deleted. wt: wild-type; del: deletion; n: total number; BCP-ALL: B-cell precursor acute lym-
phoblastic leukemia.
Table 4. Characteristics of lymphoid tumors derived from single and intercrossed Btg1 and Ikzf1 knockout lines.
Genotype Tumor incidence Mean Tumor P-valuea
(% mice) age phenotype Ikzf1+/- Btg1+/- Btg1–/–
(months)
Wild-type 3/49    (6%) 16.4 B-cell lymphoma - - -
Ikzf1+/- 5/36    (14%) 12.4 T-cell leukemia - 0.271 0.703
Btg1+/- 2/34    (6%) 15.8 T-cell leukemia 0.271 - 0.143
Btg1+/-;Ikzf1+/- 10/35  (29%) 13.6 T-cell leukemia 0.134 0.013 0.231
Btg1–/– 6/33    (18%) 17.4 T-cell leukemia 0.703 0.143 -
Btg1–/–;Ikzf1+/- 12/30  (40%) 9.4 T-cell leukemia 0.011 0.001 0.026
aChi-square analysis comparing incidence of T-cell leukemia to indicated genotype at 18 months. 
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BTG1 modifies glucocorticoid resistance mediated by
loss of IKZF1
While these experiments confirm the genetic interaction
between BTG1 deletions and IKZF1 aberrations during
leukemogenesis, they do not explain the poor outcome
observed in patients showing a combined loss of BTG1
and IKZF1. Recently, we established that inferior outcome
related to IKZF1 deletions in BCP-ALL is correlated with
an attenuated in vivo day 8 prednisolone response and
increased GC resistance in IKZF1-deleted primary
leukemic cells, as determined by in vitro MTT assays.6
These results could be recapitulated using primary splenic
B cells isolated from Ikzf1+/-mice, which revealed that non-
leukemic Ikzf1+/- B cells are also less sensitive towards GC-
induced apoptosis.6 Based on our previous findings that
BTG1 regulates glucocorticoid receptor activation,37 we
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Figure 3. Leukemia incidence and phenotype of Btg1 knockout mice intercrossed with haplodeficient Ikzf1 animals. (A) Kaplan-Meier survival curve indicates the
leukemia event-free survival in wild-type, Ikzf1+/-, Btg1+/-, Btg1+/-;Ikzf1+/-, Btg1-/-, and Btg1-/-;Ikzf1+/- mice over a time period of 17 months. Leukemia incidence is signif-
icantly increased in Btg1-/-;Ikzf1+/- mice as compared to Ikzf1+/- mice (P=0.011). (B) Peripheral blood smear stained with Giemsa and immunohistochemistry for CD3
on the lung and liver tissues of diseased Ikzf1+/-, Btg1-/-,  Btg1+/-;Ikzf1+/-, and Btg1-/-;Ikzf1+/- mice. (C) Quantification of blast counts in peripheral blood smear stained
with Giemsa of diseased wild-type, Ikzf1+/-, Btg1-/-,  Btg1+/-;Ikzf1+/- and Btg1-/-;Ikzf1+/- mice (n=3). The percentage of leukemic blasts is indicated. ***P<0.001. (D)
Quantification of T-cell (CD3) infiltration into the liver and lungs of diseased wild-type, Ikzf1+/-, Btg1-/-, Btg1+/-;Ikzf1+/- and Btg1-/-;Ikzf1+/- mice (n=3) using FIJI software.
Data are represented as the positively stained area divided by the total area measured, with standard errors of the mean P-values (two-sided t-test). *P<0.05,
**P<0.01, and ***P<0.001. (E) T-cell receptor beta 2 (Trb2) gene rearrangement analysis by PCR on control tissue, B-cell lymphoma derived from wild-type mice
(#3863), and T-cell leukemias derived from Ikzf1+/- (#13135, #350), Btg1-/- (#160), Btg1+/-;Ikzf1+/- (#5103 and #5102) and Btg1-/-;Ikzf1+/- mice (#9073, #7169, #7173).
(F) Flow cytometry analyzing CD4 and CD8 expression on T-cell leukemia samples of two Ikzf1+/-, Btg1-/-,  Btg1+/-;Ikzf1+/- and Btg1-/-;Ikzf1+/- mice. WT: wild-type; M: 1 kb
DNA ladder marker; Ctrl: control DNA.
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investigated whether loss of BTG1 would impact the GC
response in primary murine B cells. To this end, B cells iso-
lated from WT, Btg1-/-, Ikzf1-/- and Btg1-/-;Ikzf1+/- mice, and
obtained after lipopolysaccharide activation, were stimu-
lated for 48 hours with increasing concentrations of pred-
nisolone or dexamethasone and subjected to MTS assays
to assess relative cell survival. While Btg1-deficiency alone
had no effect on GC-induced apoptosis, Ikzf1-haplodefi-
cient B cells showed enhanced cell survival as compared to
WT (Figure 4A), similar to our previous findings.6
Importantly, Btg1-/-;Ikzf1+/- B cells showed an even stronger
resistance to GC-induced apoptosis when compared to
Ikzf1+/- B cells (P<0.001). These findings were confirmed
by AnnexinV staining, demonstrating a significantly small-
er apoptotic fraction in Btg1-/-;Ikzf1+/- B cells relative to
Ikzf1+/- B cells (P<0.001) (Figure 4B). Analyses of primary
Btg1-/-, Ikzf1+/- and Btg1-/-;Ikzf1+/- thymocytes revealed no
differential sensitivity to GC-induced apoptosis as com-
pared to WT (Online Supplementary Figure S6A). Next, we
assessed whether loss of Btg1 and Ikzf1 would promote
resistance in B cells to other chemotherapeutic drugs com-
monly used in the treatment of BCP-ALL patients, includ-
ing 6-mercaptopurine, doxorubicin, vincristine and
asparaginase. However, Btg1-/-;Ikzf1+/- and Btg1-/-;Ikzf1+/- B
cells showed similar cell survival in comparison to control
cells (Online Supplementary Figure S6B). 
Together, these data argue that loss of tumor suppressor
BTG1 enhances GC resistance in the context of IKZF1
deletions, which may explain the inferior treatment out-
come observed in patients showing combined loss of
BTG1 and IKZF1.
Discussion
BCP-ALL is a heterogeneous disease characterized by
recurrent deletions enriched in specific genetic subtypes.1
For instance, it is known that deletions affecting the tran-
scriptional co-regulator BTG1 are unevenly distributed
among cytogenetic subgroups, as we and others have
shown that BTG1 deletions are strongly enriched in ETV6-
RUNX1-positive leukemia as well as BCR-ABL1-positive
ALL.30,31,38 The presence of these lesions in such distinct
BCP-ALL subgroups may relate to the fact that deletions of
IKZF1 and BTG1 appear to be the result of illegitimate
RAG recombination,30 as is the case for several of the other
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Figure 4. Glucocorticoid resistance of B cells isolated from Btg1 knockout mice intercrossed with haplodeficient Ikzf1 animals. (A) Splenic B cells isolated from
wild-type, Ikzf1+/-, Btg1-/- and Btg1-/-;Ikzf1+/- mice were activated by LPS for 48 hours and subsequently treated in vitro for 48 hours with increasing concentrations of
prednisolone (PRED, left panel) or dexamethasone (DEX, right panel) and analyzed by MTS assay (n=6). All values were normalized to untreated (UT) B cells. Error
bars represent ± standard error of the mean (SEM). P-values were calculated based on the differences of the best-fit curve using two-way ANOVA. (B) AnnexinV/7-
AAD staining of WT, Ikzf1+/-, Btg1-/- and Btg1-/-;Ikzf1+/- B-lymphocytes after 2 mM prednisolone or 5 mM dexamethasone treatment for 48 hours (n=4). The fraction of
AnnexinV-positive cells was determined. Data represent means, and error bars represent SEM. P-values (two-sided t-test) are indicated. ***P<0.001.  
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commonly deleted genes, such as EBF1 and PAX5. In addi-
tion to these earlier observations, we find a specific co-
occurrence of BTG1 and IKZF1 gene deletions across cyto-
genetic subtypes, suggesting that the combined loss of
BTG1 and IKZF1 may actively contribute to leukemogen-
esis. Previous studies, mostly carried out in mouse models,
revealed that Ikzf1 and Arf alterations in BCR-ABL1-posi-
tive ALL synergize to promote the development of
leukemia by conferring stem cell-like properties.39 This
leads us to hypothesize that the preponderance of
BTG1;IKZF1 double-deletions in this particular subgroup
may have similar consequences, although this remains to
be assessed in well-established BCR-ABL1-positive mouse
models. As BTG1 and IKZF1 deletions also (co)occur in
lymphoid blast crises of chronic myeloid leukemia
(CML),7,31 it will be interesting to study if and how the
combined loss of BTG1 and IKZF1 drive the progression
of this disease. Of all the common copy number losses
analyzed in our study, including CDKN2A/B, PAX5, EBF1,
and RB1, only loss of BTG1 appears to worsen the out-
come of IKZF1-deleted ALL. Our data are consistent with
the findings of Moorman et al. showing that specific com-
binations of different deletions impact the outcome in
BCP-ALL.40 
A number of different knockout mouse models have
provided insight into the role of commonly deleted tran-
scription factors in early hematopoiesis and spontaneous
tumor incidence. It is evident that several of these tran-
scriptional regulators play an important role as lymphoid
specification factors and are essential for normal lym-
phopoiesis.41-44 However, in the mouse, loss of these early
B-cell transcription factors affected in BCP-ALL, such as
E2A45 and IKZF1,46 gives rise to T-cell malignancies. E2a-
deficient tumors are characterized by a strong increase in
c-Myc expression,45 an oncogene known to promote the
development of T-cell lymphomas.47 Similarly, while
IKZF1 deletions predominantly occur in human BCP-ALL,
heterozygous Ikzf1 knockout and dominant-negative Ikzf1
mice develop T-cell malignancies exclusively, which has
been attributed to activation of the Notch pathway.36,48 In
our studies we observed a lower incidence of T-cell
leukemia in mice as compared to what has been reported
for some other genetically engineered Ikzf1 mouse mod-
els, where expression of dominant-negative isoforms or
hypomorphic knockout alleles of Ikzf1 yielded a higher
susceptibility to T-cell malignancies.35,36,48 Similar to mice
heterozygous knockout for Ikzf1, Btg1 knockout mice
develop T-cell leukemia, while BTG1 deletions are almost
exclusively found in human BCP-ALL.30 However, consis-
tent with our finding that monoallelic BTG1 deletions are
enriched in human BCP-ALL cases with IKZF1 aberra-
tions, Btg1+/-;Ikzf1+/- mice are more prone to develop
leukemia relative to Btg1+/- single knockout mice (P=0.013).
In addition, we observed a significant acceleration in the
onset of disease in Btg1-/-;Ikzf1+/- mice as compared to 
Btg1-/- (P=0.026) or Ikzf1+/- mice (P=0.011), indicating that
loss of these tumor suppressor genes cooperates during
leukemogenesis. Genomic DNA analyses further indicate
that both the wild-type Btg1 allele and Ikzf1 allele are
maintained in the Btg1+/-;Ikzf1+/- leukemias (data not shown),
arguing that Btg1 and Ikzf1 dosage contribute to leukemia
development. These data confirm that BTG1 acts as a
tumor suppressor gene that cooperates with IKZF1 loss
during leukemia development.
Another important finding in this study is that BTG1
deletions define a high-risk group within the IKZF1-delet-
ed subtype. Our finding that loss of BTG1 specifically
enhances GC resistance mediated by Ikzf1-haplodeficien-
cy implies that the prognostic value of BTG1 and IKZF1
deletions could be dependent on the upfront treatment
and dose of synthetic glucocorticoids used. However, this
remains to be established in future studies. The relation
between BTG1 deletions and inferior outcome was recent-
ly confirmed with the analyses of a relapsed BCP-ALL
cohort, showing that BTG1 and NR3C1 deletions were
associated with a higher risk of disease progression.49
Collectively, our data demonstrate that BTG1 is a prog-
nostic factor and regulator of the GC response, particularly
in the context of IKZF1-deletions. 
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